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Abstract 
Objective. In this study, we compare the prevalence of HT in RA and OA patients, exposed 
to high- and low-grade chronic inflammation, respectively , to assess the possible association 
between chronic inflammation and HT.  
Methods. A total of consecutive 627 RA and 352 OA patients were enrolled in this 
multicentric study. HT was defined as a systolic blood pressure (BP) ≥140 and/or diastolic BP ≥90 
mmHg or current use of any antihypertensive drug. Overweight/obesity was defined as body mass 
index (BMI) ≥25, and patients ≥65 years old were considered elderly.  
 Results. The prevalence of HT was higher in the OA group than in the RA group [73.3% 
(95%CI 68.4, 77.7) and 59.5% (95%CI 55.6, 68.4) P<0.001 respectively]. When the results were 
adjusted for age and BMI the HT prevalence was similar in both groups [RA 59%(95%CI 55.1, 
63.8) OA 60%(95%CI 58.4, 65.0)].  In both groups, the prevalence of HT was higher in the elderly 
and those who were overweight  than in the younger patients and those with a BMI <25 . 
Overweight (BMI ≥25) and age ≥65 were independent predictors of HT in multivariate logistic 
regression model, which show no association of HT and the disease (RA or OA).  
Conclusion. The results indicated a robust association of age and BMI with HT prevalence 
in both RA and OA. The difference in HT prevalence between RA and OA is rather due to age and 
BMI then to features of the disease, putting into question specific association of HT with RA.  
 Key words: Rheumatoid arthritis, Osteoarthritis, Hypertension
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Introduction 
Excessive cardiovascular (CV) morbidity and mortality leading to premature death is 
common in rheumatoid arthritis (RA) patients. The mechanism of this co-morbidity is not well 
understood. Chronic systemic inflammation is thought to have a pivotal role in increased CV 
disease risk in RA, contributing to vascular damage (endothelial dysfunction, accelerated 
atherosclerosis, and atherosclerotic plaque instability) [1]. 
Among the classic CV risk factors, hypertension (HT) has a prominent role in RA patients 
[1,2]. An increased prevalence of HT in RA patients was found in a number of studies, but not in 
all. A 52-73% prevalence of HT in RA patients was found in the studies with a large number of 
patients that used the current definition of hypertension [3]. The mechanisms leading to frequent 
HT in RA patients are not clear; the association is likely due to a complex interplay of various 
factors, including chronic systemic inflammation [3]. 
CV co-morbidities, particularly HT, have not been investigated in osteoarthritis (OA) 
patients as extensively as in RA patients. The prevalence of CV disease in OA was found to be 
approximately 55% [4,5]. The reported prevalence of HT in OA was 40% in one study [6] and 75% 
in another [7]. The studies comparing CV disease risk in RA and OA are rather scarce. The CV 
disease risk and the presence of CV disease risk factors in OA were found to be lower [8] or similar 
[9] to those in RA. The CV disease risk in OA has been attributed to a high prevalence of classic 
CV disease risk [9], and in the case of HT, to medication, especially the use of non-steroidal anti-
inflammatory drugs (NSAIDs) and cyclooxygenase-2 inhibitors [10]. 
The aim of this study is a comparison of HT prevalence and disease features in RA and OA 
patients. A comparison of the two diseases, which are both characterized by a chronic course and 
painful joint involvement, but with either high (RA) or low (OA) levels of chronic systemic 
inflammation [11,12], may reveal an association between various disease features and HT in 
conditions that differ in terms of the level of chronic systemic inflammation. 
 
 
Patients and methods 
In order to collect date concerning HT prevalence in RA and OA of  from all part of the 
country we preformed this multicentric cross-sectional study in collaboration with outpatient 
rheumatology clinics in regional medical centers of Croatia (Table 1). A total of 625 RA and 352 
OA patients who attended the outpatient clinics from 1 September to 31 December 2009 were 
consecutively enrolled in the study. The diagnoses of RA and OA (knee, hip and hand) were 
established by qualified rheumatologists according to the 1987 American College of Rheumatology 
 5
(ACR) classification criteria for RA [13] and the ACR criteria for OA [14,15,16]. The study 
protocol was approved by the Ethical Committee of the Dubrava University Hospital, Zagreb, the 
coordinative center of the study, and a written informed consent (according to the Declaration of 
Helsinki) was obtained from all study participants.  
All participants underwent a detailed evaluation guided by a questionnaire administered in 
all collaborative departments. The evaluation included a detailed medical history, physical 
examination and the measurement of body height and weight. Patients with ischemic heart disease 
were not included in the study. 
In order to compare this study with the study [17] the subgroups comprised all 50-70 yrs old 
RA and OA patients were selected. 
Patients ≥65 years of age were considered elderly. Body mass index (BMI) was calculated 
according to the standard formula [18], and patients with BMIs ≥25 were qualified as overweight 
(including obesity). Waist and hip circumferences were measured, and the waist-to-hip ratio (WHR) 
was calculated [19].  
Pain and the patients’ general health (GH) were assessed using the appropriate visual analog 
scales (VAS). Pain VAS (VASP) ranged from 0–10, with 10 being the most intensive pain [20]. 
General health VAS (VASGH) was part of the DAS28-CRP score [21]. VAS was represented by a 
100 mm long line on which the patients evaluated their own health, with 100 mm representing the 
best health. RA patient functional status and disease activity were assessed by the Croatian 
translation of the Health Assessment Questionnaire (HAQ)[22] and by the DAS28-CRP [20] using 
a DAS calculator [23], respectively.  
All antihypertensive and antirheumatic medications taken by the enrolled patients were 
recorded in detail (indications, dose and duration of treatment). 
Blood pressure (BP) was measured after a 5 min rest in a sitting position on the right arm 
with a mercury sphygmomanometer and a standard cuff.  The recorded BP value for each patient 
was the mean of three subsequent measurements at 5 min intervals. HA was defined according to 
the European Society of Hypertension and the European Society of Cardiology 2007 guidelines 
with BP≥140 mmHg and/or diastolic BP≥90 mmHg [18] or any BP with antihypertensive treatment. 
Newly discovered HT was defined as actual HT without HT history and was expressed as the 
prevalence and the fraction of actual HT. Uncontrolled HT was defined as HT on hypertensive 
therapy   having BP with HT values.   
Venous blood samples were collected for laboratory investigations after overnight fasting. 
The following tests were performed in the laboratories of the collaborative hospitals: erythrocyte 
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sedimentation rate (ESR),  C-reactive protein (CRP), total cholesterol (Chol), high-density 
lipoproteins (HDL), low-density lipoproteins (LDL), triglycerides (TG), creatinine and plasma 
glucose (Glc). When required, oral glucose tolerant tests (OGTT) were performed. Diabetes (DM) 
was defined by a history of  DM with current use of antidiabetic medication or fasting Glc ≥7 
mmol/L or Glc in OGTT (2 h) ≥11.1 mmol/L [24]. The same standard methods were used in all 
laboratories, and biochemical assays were performed using Olympus autoanalyzers according to the 
manufacturer’s protocol.  
Statistical analysis 
The normality of the data distribution was assessed using the Kolgomorov-Smirnov test. 
Values are presented as median [interquartile range(IQR], mean (S.D.) or percentage values as 
appropriate. Comparisons were performed with the Student’s t-test, Mann-Whitney U-test and chi-
squared test for normally, non-normally distributed and categorical variables, respectively. Binary 
logistic regression was used to assess the independency of the association of various variables with 
the prevalence of HT in RA, OA and all patients. P-values <0.05 (two-tailed) were considered 
significant. All statistical analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, 
USA). The adjustment of HT prevalence for age and BMI was made according to [25].  
 
Results 
Characteristics of RA and OA patients (Table 2).  
The proportion of female patients was higher than that of men in both the RA and OA 
groups. In comparison with OA, RA was characterized by younger age, a lower proportion of 
elderly patients, a longer duration of the disease, a higher proportion of smokers (ever and current), 
lower BMI and WHR, a lower proportion of overweight/obese patients, similar VASP and VASGH, 
and lower proportions of dyslipidemic and DM patients.  
Laboratory investigations showed higher plasma CRP concentrations and ESR, and lower 
Chol, TC and Glc plasma concentrations in the RA group. HDL, LDL and plasma creatinine 
concentrations were similar in both groups of patients.  
Prevalence of HT in RA and OA patients (Table 3) 
The prevalence of HT was lower in the RA group than in the OA group. However when the 
results were adjusted for age and BMI the prevalence was similar in both groups. Also HT 
prevalence in RA and OA of 55-70 yrs subgroups was similar.  
The proportion of patients with a history of HT was lower the RA group than in the OA 
group. The prevalence of newly discovered HT was similar in RA and OA, but newly discovered 
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HT comprised a higher fraction of actual HT in RA than in OA patients. The rate of uncontrolled 
HT, expressed as fraction of treated HT was similar in the RA and OA groups. 
In both RA and OA, the prevalence of HT was higher in the elderly and overweight/obese 
patients than in patients under 65 years of age or with BMI values <25. When RA and OA patients 
less than 65 years of age were sorted according to both age and BMI, the prevalence of HT was 
higher in overweight/obese patients than in those with BMI values <25. In the elderly, this 
difference was smaller and statistically insignificant.  
Taking cut-off for CRP concentration of 5 mg/L, the prevalence of HT was higher in the RA 
group with higher CRP concentration then with lower. In the OA there was no such difference.   
In both RA and OA patients, the prevalence of HT was higher in DM than in nondiabetic 
patients. Upon comparing RA and OA, the prevalence of HT in DM was similar in both groups and 
that in nondiabetics was higher in the latter group than in the former group.  
Regarding smoking habit, HT prevalence was higher in non-smoker and ex-smokers then in 
current smokers in both groups. 
The HT prevalence was similar in non-steroidal anti-inflammatory drugs (NSAIDs) users 
and non-users in both the RA and OA groups. In RA group there was no difference in HT 
prevalence between glucocorticoid users and non-users, but in current users the prevalence of HT 
was higher in patients taking glucocorticoids more then less of 3 months.  
Results regarding comparison of HT and NT (normotensive) subgroups of RA and OA 
patients and comparison of hypertensive RA and OA patients are shown in table 1-S and 2-S. (see 
supplementary data available at Rheumatology online) 
Multivariate analysis 
Variables that were significantly different comparing the HT and NT subgroups in RA and 
OA groups were introduced in logistic regression the models. The variables that were independently 
associated with HT presence in RA and OA were age and BMI (see see supplementary data 
available at Rheumatology online table 2-S). To analyze mutual contribution of these variables to 
HT prevalence in all patents  in a logistic regression model age and BMI as numerical variables and 
the disease (RA or OA) as categorical variable were introduced (table 4). The analysis indicated 
independent association of age and BMI with HT prevalence without contribution of features of the 
disease (RA or OA). From the date generated by the model adjusted  HT prevalence were calculated 
(table 3). 
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Discussion  
The characteristics of our RA and OA patients and their differences are consistent with 
reported epidemiological and clinical features of the diseases [26], including a higher prevalence in 
females than in males in both RA and OA; higher age in OA and a longer duration of the disease for 
RA, higher proportion of smokers in RA, reflect a greater increase in OA prevalence with age and a 
lower age of onset of RA; and a strong association of BMI with OA and an association of RA with 
smoking. 
The prevalence of HT is associated with age [27] and BMI [28], which explains the higher 
prevalence of HT in OA. When the results were adjusted for age and BMI the HT prevalence in RA 
and OA was similar. 
 In comparison with others studies, the prevalence of HT in RA group was lower than that 
reported in a similar study of Panoulas et al. [17], The patients in that study was older then in this 
study [63.1( 55-69.6) v  59.00(52.00-68.00) median (IQR) respectively].  Similar HT prevalence in 
55-70 yrs RA subgroups and that in [17] study indicate that the differences in HT prevalence 
between this study and study [17] is due to difference in age of the patients. Regarding OA, our 
finding is similar to that reported in one of the previous studies [7].  
The overall prevalence of HT in Croatia (44.2%) is similar to that in other European 
countries [29].When age was taken into account, only the higher prevalence of HT in OA patients 
under 65 years old, compared with the prevalence in the general Croatian population, could be 
assumed (Fig. 1). However, this visual comparison of prevalence and the confidence intervals is 
rather insufficient, and investigations with proper control groups are needed.   
Upon comparing the rates of newly discovered, treated with antihypertensive therapy and 
uncontrolled HT in our study with rates in the general Croatian population [29] and rates described 
for RA [28], there was a lower rate for newly discovered HT (reference 29: 44.5%; reference 28: 
39.4% vs. this study: 29.9% and 18.6% for RA and OA, respectively), a higher rate for treated HT 
(reference 29: 44.5%; reference 28: 60.6% vs. this study: 75.1% and 86.0% for RA and OA, 
respectively) and a lower rate for uncontrolled HT (reference 29: 85.6%; reference 28: 78.36% vs. 
this study:  41.0% and 50.8% for RA and OA, respectively). This improvement in HT screening and 
therapy in rheumatologic diseases is probably result of recently increased awareness of HT 
prevalence in RA [17,30] 
In both RA and OA, the association of HT with various variables followed that of HT in 
general (increased HT prevalence with age and BMI, association of HT with DM and with 
metabolic variables associated with HT, (see supplementary data available at Rheumatology online 
table 1-S)[18] and were similar to those described for RA [17].  
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Due to the change in body composition (loss of lean body mass with an increase in fat body 
mass) in RA, BMI is lower for a given fat mass [31], which should be taken in account when BMI 
in RA is compared with that in other conditions. Alternatively, we measured WHR, which 
correlates with visceral adipose tissue and CV disease risk [19]. The higher WHR in OA (all 
patients) indicates a higher visceral adiposity in OA than in RA. Lower BMI values and similar 
WHRs in HT RA versus HT OA patients may indicate an underestimation of overweight and 
obesity in the former group (see Supplementary data table 1-S).  
The prevalence of HT in subgroups defined by both age and BMI (higher in the subgroup 
with BMI≥25 than BMI<25 in patients <65 years of age and similar regarding BMI in patients ≥65 
years of age) indicated a stronger association between age and HT than between BMI and HT. 
Smoking has been shown to be a risk factor for HT in general [18], and an association with 
HT in RA has been described [17]. The lack of association of smoking with HT in both RA and OA 
in our study might be explained by the higher age of nonsmokers versus current smokers and ex-
smokers in both the RA and OA groups (results not shown).  
Higher values for markers of inflammation (ESR, CRP concentration) in RA compared to 
OA, as well as in the RA HT subgroup compared to NT RA (see supplementary data available at 
Rheumatology online 1-S) and higher HT prevalence in CRP>5mg/L than in CRP<5mg/L  RA 
subgroup, show a higher grade of systemic inflammation in RA than in OA and an association of 
HT with degree of systemic inflammation in RA, respectively. This association was rather weak 
because it was not expressed in the multivariate analysis (see supplementary data available at 
Rheumatology online table 2-S), and there was no association of disease activity and HT assessed 
by the DAS28-CRP (see supplementary data available at Rheumatology online table 1). In a 
retrospective study, an association between CRP concentration and HT was shown in RA [2], 
whereas no association of HT with either CRP or DAS was found in the cross-sectional study [17]. 
A causative role of systemic inflammation in the pathogenesis of HT in RA was proposed, but there 
was no conclusive evidence for that hypothesis [3,17]. Cross-sectional studies with one point of 
measurement for inflammatory markers and HT, such as this study and that reported in [17], are not 
adequate to answer questions regarding the duration of disease, and future longitudinal studies are 
essential.  
Antirheumatic therapy may provoke HT or interfere with its control, particularly in the case 
of NSAIDs used for the treatment of OA [10] and RA and for various DMARDs and GCs used to 
treat RA [3]. Our results, which showed no association of HT with NSAID use in RA and OA and 
an association of HT with leflunomide use (see supplementary data available at Rheumatology 
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online, table 1-S) and with the duration of GC use in RA  were similar to the findings of others for 
RA [17,32]. 
Finally, age and BMI were the only variables that were independently associated with HT in 
both the RA and OA groups and with difference in HT presence between RA and OA. However, 
age and BMI, which are higher in OA than in RA, act as confounding variables that may obscure 
the association of other variables with HT, particularly systemic inflammation [33], and the 
influence of these variables could not be excluded.  
Confounding effect of age and BMI has to be taken in account in comparison of HT 
prevalence between RA and OA and with other conditions to avoid erroneously conclusions.   
In conclusion, this cross-sectional study has shown a robust association of age and BMI with 
HT prevalence in both RA and OA. The difference in HT prevalence between RA and OA is rather 
due to age and BMI than due to features of the disease, putting into question specific association of 
HT and RA [3].  
Indirect comparison showed that HT prevalence in RA in our study was similar to the 
Croatian general population. For OA, HT prevalence was higher than that of the Croatian general 
population under 65 years old and similar to that over 65 years old.  
Key messege 
The difference in HT prevalence between RA and OA is due to age and BMI. 
Confounding effect of age and BMI could lead to erroneously conclusions on HT 
prevalence.   
HT prevalence in RA is similar to that in general population in Croatia.    
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Table 1-S. Hypertensive and normotensive patients in RA
a
 and OA
b
 
 RA (N=627)  P value (HTRA 
vs. HTOA) 
OA (N=352) 
 HT
c
 (N=373)  NT
d
 (N=254) P-value( HT vs. 
NT) 
 HT (N=258) NT  (N=94) P-value (HT vs. 
NT) 
Sex female, n[%(95%CI
e
)] 
 
314  
[84.2 (80.2, 87.6)] 
208  
[81.0 (75.7, 85.3)] 
0.450 0.435 223  
[86.4 (81.7, 90.0)]  
72   
[76.6 (67.1, 84.0)] 
0.027 
Age, yrs 63.0 (56.0-70.0) 54.0 (45.0-62.0) <0.001 <0.001 69.0 (61.0-74.0)  59.0 (50.0-69.0) <0.001 
Aged ≥65 yrs, 
n[%(95%CI)]  
 
157  
[42.1 (37.2, 47.2)] 
51  
[20.1 (15.6, 25.5)] 
<0.001 <0.001 167  
[64.7 (58.7, 70.3)] 
32  
[34.0 (25.2, 44.0)] 
<0.001 
Disease duration (yrs) 8.0 (3.0 -16.0)  5.0 (2.0 -12.0)  0.002 0.008 6.00 (2.0-12.0)  3.0 (1.0-7.0) <0.001 
HT awareness (yrs) 7.0 (3.0-13.0) 0 ND
g 
0.002 9.0 (5.0-16.0) 0 ND 
BMI
f
 27.17  
(24.66 - 30.26)  
25.30  
(22.58 -28.03)  
<0.001 <0.001 30.41 
(26.73 -33.00)  
27.50  
(24.96 - 31.03)  
<0.001 
BMI≥ 25 n[%(95%CI)] 
 
266  
[71.3 (66.5, 75.7)] 
129  
[50.7 (44.6, 56.8)] 
<0.001 <0.001 218  
[85.2 (80.4, 89.0)] 
70  
[74.5 (64.8, 82.2)] 
0.020 
W/H
h
 ratio 0.90  
(0.85 - 0.95)  
0.86  
(0.80 - 0.92)  
<0.001 0.464 0.90  
(0.85 - 0.96)  
0.89  
(0.82 - 0.96)  
0.177 
VASP
i
 50.00  
(39.00 - 70.00)   
50.00 (25.25 -
 70.00)  
0.007 0.340 55.00  
(40.00 - 70.00)   
40.00  
(28.00 - 50.00)   
<0.001 
VASGH
j
 50.00  
(30.00 - 70.00)   
42.00  
(20.00 - 60.00)  
0.064 0.618 50.00  
(30.00 - 64.50)   
43.50  
(30.00 - 60.00) 
0.147 
HAQ
k
 1.50  
(0.70 - 2.13)      
1.19  
(0.60 - 1.88)   
0.002  ND
 
ND ND 
DAS28-CRP
l 
4.41 (1.52) 4.21 (1.58) 0.129  ND ND  
Dyslipidemia, 
n[%(95%CI)] 
173 
[46.4 (41.4, 51.5)] 
76 
[29.9 (24.6, 35.8)] 
<0.001 0.030 147 
[57.0 (50.9, 62.9)] 
37 
[39.4 (30.1, 49.5)] 
0.010 
DM
m
 n[%(95%CI)] 47 
[12.6 (9.6, 16.4)] 
13 
[5.1 (3.0, 8.5)] 
0.002 0.010 52 
[20.2 (15.8, 25.5)] 
7 
[7.4 (3.6, 14.5)] 
0.005 
 
Laboratory data        
ESR
n
  28 (15 – 45)  22 (12 – 40)   0.007 <0.001 15 (9- 24)      12 (8 – 20)      0.114 
CRP
o
 (mg/L) 9.40 
(4.00-21.00)    
6.70 
(2.38-16.94)  
0.007 <0.001 2.95 
(1.30-3.83)    
2.00  
(1.40 – 3.10)   
0.016 
Chol
p
 (mmol/L)  5.61  
(4.90 – 6.50)    
5.30 
(4.73 – 5.90)    
<0.001 0.565 5.80  
(4.84 – 6.60)    
5.70  
(4.80 – 6.38)   
0.263 
TG
q
 (mmol/L) 1.45  
(1.10 – 1.90)    
1.22 
(0.93 – 1.60)  
<0.001  <0.001 1.700  
(1.30 – 2.31)  
 1.60  
(1.09 – 1.90)   
0.008     
 3 
HDL
r
 (mmol/L) 1.40  
(1.19 – 1.80)    
1.43  
(1.20 – 1.79)  
0.403   0.920 1.40  
(1.19 – 1.70)     
1.50  
(1.20 – 1.80)   
0.073     
LDL
s
 (mmol/L) 3.40  
(2.90 – 4.05)    
3.12  
(2.70 – 3.70)  
<0.001  0.038 3.23  
(2.50 – 3.969     
3.01  
(2.30 – 3.73)  
0.100  
Glc
t
 (mmol/L) 5.00  
(4.50 – 5.60)    
4.90  
(4.40 – 5.30)  
0.007  <0.001 5.50  
(4.90 – 6.00)    
5.40  
(5.00 – 5.89)  
0.350  
Creatinine (mmol/L) 78.00  
(69.00 – 88.75)    
74.00  
(65.00 – 82.25)  
<0.001  0.768 79.00  
(68.00 – 89.00) 
78.00  
(70.00 – 84.25)  
0.629  
RF
u
 (IU/mL) 
 
46.3  
(10.0-155.0) 
28.8 
(8.0-139.5) 
0,268 ND ND ND ND 
        
Smoking habit        
Nonsmokers 
n[%(95%CI)] 
 
221  
[59.2 (54.9, 64.9)] 
130  
[51.2 (45.1, 57.3)] 
0.046 <0.001 189  
[73.3 (67.6, 78.3)] 
56  
[59.69 (49.6, 69.0)] 
0.014 
Exsmokers, n[%(95%CI)] 
 
 89  
[23.9 (19.9, 28.5)] 
 50  
[19.7 (15.3, 25.0)] 
0.217 0.010   40  
[15.5 (11.6, 20.4)] 
15  
[16.0 (9.9, 24.7)] 
0.917 
- duration yrs. 20.00 
 (13.50-30.00) 
20.00 
(10.00-25.00) 
0.122 0.449 20.00 
(10.00-30.00) 
15.00 
(7.00-20.00) 
0.170 
Current smokers 
n[%(95%CI)] 
 
 63  
[16.9 (13.4-21.0)] 
 74  
[29.1 (23.9-35.0)] 
<0.001 0.048   29  
[11.2 (7.9-15.6)] 
23  
[24.5 (16.9-34.0)] 
0.002 
- duration yrs. 30.00 
(20.00-40.00) 
27.00 
(20.00-34.00) 
0.039 0.423 30.00 
(22.00-33.50) 
28.00 
(20.00-37.00) 
0.462 
- cigarettes/day 15 (10-20) 10 (10-20) <0.001 0.041 10 (4-20) 20 (10-20) 0.001 
 
Medication         
Antirheumatics        
NSADs
v
 users 
n[%(95%CI)] 
 
180  
[48.3 (43.3, 53.4)] 
133  
[52.6 (46.5, 58.7)] 
0.328 0.002 163  
[63.2 (57.2, 98.9)] 
69  
[73.4 (63.7, 81.3)] 
0.073 
MTX
w
 users, 
n[%(95%CI)] 
180  
[48.3 (43.3, 53.4)] 
132  
[52.0 (45.9, 58.1)] 
0.362 ND 0 0 ND 
Leflunomide  users 
,n[%(95%CI)] 
 
59  
[15.8 (12.5, 19.8)] 
26  
[10.3 (7.1, 14.6)] 
0.048 ND 0 0 ND 
Chloroquine users, 
n[%(95%CI)] 
 
26  
[10.2 (7.5, 13.7)] 
33  
[8.8 (5.9, 12.9)] 
0.559 ND 0 0 ND 
Sulphosalazine users, 
n[%(95%CI)] 
96  
[25.7 (21.5, 30.4)] 
61  
[24.1 (19.3, 29.7)] 
0.659 Nd 0 0 ND 
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Glucocorticoide        
- users, n[%(95%CI)] 
 
314  
[84.2 (80.2, 87.6)] 
213  
[83.9 (78.9, 87.9)] 
0.913 ND 0 0 ND 
- duration  (month)  4.0 (1.0-8.0) 2.0 (1.0-6.0) 0.008 ND 0 0 ND 
- dose (mg/day) 20.0 (10.0-20.0) 20.0 (10.0-20.0) 0.632 ND 0 0 ND 
Anti-TNF
y
, n[%(95%CI)] 
 
16  
[4.3 (2.7, 6.9)] 
24  
[9.5 (6.5, 13.7)] 
0.009 ND 0 0 0 
Analg users,  
n[%(95%CI)] 
 
134  
[35.9 (31.2, 40.9)] 
71  
[28.0 (22.8, 33.8)] 
0.037 0.945 92  
[35.7 (30.1, 41.7)] 
29  
[30.9 (22.5, 40.3)] 
0.401 
Opioids users, 
n[%(95%CI)] 
0  1 [0.4] ND ND 91  
[35.3 (29.7, 41.3)] 
30  
[31.9 (23.3, 41.9)] 
0.557 
Antihypertensives        
ACE-I
x
, n[%(95%CI)]
 
 
150  
[40.2 (35.3, 45.8)] 
0 ND 0.002 137  
[53.1 (49.0, 59.1)] 
0 ND 
BB
z
 , n[%(95%CI)] 
 
113  
[30.3 (25.9, 35.1)] 
0 ND 0.930 79  
[30.6 (25.3, 36.5)] 
0 ND 
DIUR
aa
 , n[%(95%CI)] 121  
[32.4 (27.9, 37.3)] 
0 ND 0.004 113  
[43.8 (37.9, 49.9)] 
0 ND 
ATRA
ab
 , n[%(95%CI)] 13  
[3.5 (2.1, 5.9)] 
0 ND 0.173 15  
[5.8 (3.5, 9.4)] 
0 ND 
CCB
ac
, 
 
n[%(95%CI)] 94  
[25.2 (21.1, 29.2)] 
0 ND 0.001 96  
[37.2 (31.5, 43.2)] 
0 ND 
Anti-HT
ad
 , drugs. no  2 (1-2) 0 ND 0.008 2 (1-3) 0 ND 
Anti-HT users, 
n[%(95%CI)] 
 
280  
[75.1 (70.5, 79.2)] 
0 ND 0.002 222  
[86.0 (81.2, 89.7)] 
0 ND 
Statins, n[%(95%CI)] 
 
68  
[18.2 (14.6, 22.0)] 
17  
[6.7 (4.2, 10.5)] 
<0.001 0.003 75  
[29.1 (23.9, 34.9)] 
10  
[10.6 (5.9, 18.4)] 
0.001 
      Results are expressed as percentages and 95%CI, median values (interquartile range) or mean values (standard deviation) as appropriate.  
a
RA, rheumatoid arthritis; 
b
OA, osteoarthritis; 
c
HT, hypertenson; 
d
NT, normotension; 
e
CI, confidence interval, 
f
BMI, body mass index; 
g 
ND, non-done, 
h
W/H, waist/hip, 
i
VASP, pain visual analog scale; 
j
VASGH, General health visual analog scale; 
k
HAQ,
 
Health assessment questionnaire; 
l
DAS28-CRP, Disease activity score, 28 joints and C-
reactive protein; 
m
DM, diabetes mellitus; 
n
ESR, erythrocyte sedimentation rate; 
o
CRP, C-reactive protein; 
p
Chol, plasma cholesterol, 
q
TG, plasma trigycerides, 
r
HDL, high-
density lipoprotein, 
s
LDL, low-density lipoprotein; 
t
Glc, plasma glucose; 
u
RF, rheumatoid factor; 
v
NSAIDs, non-steroidal anti-inflammatory drugs; 
w
MTX, methotrexate, 
y
TNF, tumor necrosis factor; 
x
ACE-I, angiotensin-converting enzyme inhibitors; 
z
BB, β-blockers; 
aa
DIUR, diuretics; 
ab
ATRA, angiotensin-II receptor antagonists; 
ac
CCB, 
calcium channel blockers; 
ad
Anti-HT, antihypertensives.     
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Comments to table 1-S 
Comparison of HT and NT (normotensive) RA and OA patients  
In both RA and OA patients, the HT subgroup was characterized by older patients and a 
higher proportion of the elderly, a longer duration of the disease (RA or OA), higher BMI and a 
greater proportion of overweight/obese patients, higher VASP, a higher proportion of dyslipidemic 
and DM patients and higher plasma LDL and triglyceride concentrations, compared with the NT 
patients. VASGH and HDL values were similar in HT and NT in both RA and OA patients. 
The following variables had dissimilar differences between HT and NT patients in RA and 
OA: the proportion of female HT and NT patients was similar in the RA group, but higher in the 
HT patients of the OA group; WHR was higher in HT RA patients than in NT RA patients, but 
similar in HT and NT OA patients; ESR, CRP, Chol, LDL, and Glc concentrations were higher in 
HT than in NT patients in the RA group, but were similar in the HT and NT patients in the OA 
group. (Statistically significant difference for CRP in OA was so small that had no clinical 
significance). 
   Regarding variables measured only in the RA group, DAS28-CRP values and RF 
concentration were similar in the HT and NT patients, whereas HAQ was higher in the HT than in 
the NT patients. 
Comparing HT and NT patients regarding smoking the HT group had a higher proportion of 
nonsmokers, a similar proportion of ex-smokers, and a lower proportion of current smokers than did 
the NT group for both RA and OA. The smoking duration of ex-smokers was similar in among the 
HT and NT patients with RA and with OA.  For current smokers, the duration of smoking was 
similar and the number of cigarettes per day was higher in HT RA patients than in NT RA patients 
and lower in HT OA patients than in NT OA patients.  
Regarding medications there were no statistically significant differences in the proportions 
of users of non-steroidal anti-inflammatory drugs (NSAIDs) between HT and NT patients in either 
the RA or OA group. The same was found for RA-specific medication, including various disease 
modifying anti-rheumatic drugs (DMARDs), glucocorticoids (GCs) and anti-tumor necrosis factor 
(anti-TNF) drugs. An exception to this finding was leflunomide, with a higher proportion of users in 
HT group and the use was associated with a higher prevalence of HT. than in nonusers (69.4 in 
users % vs. 58.1%, , P=0.048). Regarding GCs, only the duration of therapy was associated with 
HT; duration was longer in HT than in NT patients.  
The proportions of antihypertensive users, in terms of their general use and in terms of 
specific drugs, were higher in OA HT patients than in the RA HT patients, except in the case β-
 6
blockers and angiotensin-II receptor antagonists, which were used by similar proportions of patients 
in both groups. 
Statins were used by a higher proportion of HT than NT patients in both the RA and OA 
groups, and the proportion of HT users was higher in OA than in RA patients.  
Comparison of hypertensive RA and OA patients  
The HT OA subgroup was characterized by higher age, a greater proportion of elderly 
patients, longer awareness of HT,  higher BMI, a greater proportion of overweight/obese patients, a 
higher proportion of dyslipidemic and DM patients, and higher TG and Glc concentrations 
compared to HT RA patients. In contrast, the disease duration (RA or OA) was longer and ESR, 
CRP and LDL concentrations were higher in HT RA than in HT OA patients. The proportion of 
females, WHR, VASP, VASGH and Chol, HDL and creatinine concentrations were similar in HT 
RA and OA patients. 
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Table 2-S. Logistic regression analysis with HT
a
 as dependent variable.  
Variable         OR (95%CI) P-value 
RA
b
 group (n=627)   
Age 1.063 (1.038-1.090) <0.001 
RA_duration 1.018 (0.985-1.053) 0.289 
BMI
c 
1.108 (1.047-1.173) <0.001 
W/R
d
 ratio 0.620 (0.042-9.193) 0.728 
VASP
e 
1.006 (0.995-1.017) 0.304 
HAQ
f 
0.972 (0.718-1.315) 0.853 
Dyslipidemia 1.316 (0.805-2.1529 0.273 
DM
g 
1.348 (0.445-4.090) 0.597 
ESR
h 
1.008 (0.995-1.022) 0.217 
Chol
i 
1.002 (0.921-1.089) 0.971 
LDL
j
 1.047 (0.806-1.360) 0.732 
TG
k 
1.206 (0.920-1.581) 0.174 
Creatinine 1.014 (1.000-1.028) 0.042 
Glc
l 
1.113 (0.874-1.418) 0.386 
Cigarette per day 0.977 (0.943-1.013 0.212 
Glucocorticoid . duration of therapy 1.036 (0.976-1.099) 0.246 
OA
m
 group (n=352) 
Age 1.052 (1.020-1.085) 0.001 
OA duration 1.036 (0.994-1.079) 0.095 
BMI
c 
1.126 (1.051-1.207) 0.001 
VASP
d 
1.023 (1.009-1.037) 0.001 
Dyslipidemia 1.818 (1.011-3.270) 0.046 
DM
e 
1.606 (0.637-4.046) 0.315 
TG
f 
1.223 (0.875-1.710) 0.239 
Cigarettes per day 0.950 (0.890-1.014) 0.126 
Variables significantly different between HT and NT subgroups (table 1-S) were introduced in the model. 
HT
a
, hypertension; RA
b
, rheumatoid arthritis; BMI
c 
, body mass index;
 
W/R
d
 ,waist/hip; VASP
e
,pain visual 
analog scale; HAQ
f
, Health assessment questionnaire;DM
g 
,diabetes mellitus; ESR
h 
erythrocyte 
sedimentation rate; Chol
i
,plasma cholesterol;LDL
j
 low-density lipoprotein, TG
k
 plasma triglicerides; Glc
l 
, 
plasma glucose, 
m
OA, osteoarthritis,. 
 
 
 
 
 
